The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients

Deger S. M., ERTEN Y., PAŞAOĞLU Ö. T., DERİCİ Ü., ALTOK K., Onec K., ...Daha Fazla

CLINICAL AND EXPERIMENTAL NEPHROLOGY, cilt.17, sa.3, ss.416-423, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s10157-012-0725-0
  • Dergi Adı: CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.416-423
  • Anahtar Kelimeler: FGF23, Dialysis, Iron therapy, Mineral metabolism, SACCHARATED FERRIC-OXIDE, FIBROBLAST-GROWTH-FACTOR, FGF23 ELEVATION, FIBROBLAST-GROWTH-FACTOR-23, HYPOPHOSPHATEMIA, OSTEOMALACIA, POLYMALTOSE, PHOSPHORUS, DISEASE, FGF-23
  • Gazi Üniversitesi Adresli: Evet

Özet

Fibroblast growth factor 23 (FGF23) is an important counterregulatory hormone for phosphate homeostasis. Since it has been reported that iron administration induces hypophosphatemic osteomalacia by triggering FGF23 synthesis, we hypothesized that iron administration might lead to a further increase in FGF23, resulting in alterations to Ca-P metabolism in a stage 5 CKD population.